Cytovale: Expanding Sepsis Risk Test Reach with $184M Funding
Deal News | Oct 31, 2024 | Breakout Ventures Associates L
Cytovale, a medical technology company, has secured $184 million in funding aimed at expanding its innovative sepsis risk test into a greater number of emergency rooms (ERs). This funding was backed by Breakout Ventures Associates, a private equity firm that has taken a keen interest in advancing medical technologies that demonstrate significant potential for impact. Cytovale's sepsis risk test is designed to provide rapid and accurate identification of sepsis risk in patients, addressing a crucial need in ER settings where early detection of sepsis can significantly improve patient outcomes. The funding will enable Cytovale to enhance its production capabilities, optimize its technology, and scale its market presence to ensure broader access to its life-saving diagnostic tool.
Sectors
- Medical Technology
- Private Equity
Geography
- United States – The expansion of Cytovale’s sepsis risk test is primarily aimed at emergency rooms in the U.S., indicating the geographical market targeted for growth.
Industry
- Medical Technology – The article focuses on Cytovale's sepsis risk test, a medical technology aimed at improving diagnostics in emergency medical settings.
- Private Equity – Breakout Ventures Associates, a private equity firm, is involved in funding Cytovale's expansion efforts, highlighting the role of private investment in scaling medical innovations.
Financials
- $184M – Funding provided to Cytovale for expanding the reach of its sepsis risk test into more emergency rooms.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Cytovale | Target Company | Company | A company specializing in sepsis risk diagnostic technology for emergency medical settings. |
| Breakout Ventures Associates | Private Equity Firm | Company | A PE firm providing $184M in funding to support Cytovale's market expansion and technological advancements. |